ClinicalTrials.gg
TerminatedNCT05155631U54_P3_CBTUpdated Nov 5, 2026Results posted

Sex Differences in Effectiveness of CBT on IBS Project 3

An interventional study of COGNITIVE BEHAVIORAL THERAPY in IBS - Irritable Bowel Syndrome, sponsored by University of California, Los Angeles. Terminated at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Early termination due to unexpected closure of Mahana app. This caused a premature end to study enrollment.
Updated Nov 5, 2026Now TerminatedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Irritable Bowel Syndrome by University of California, Los Angeles — 2 open to participants now, 2 under way, none of them phase 3. Irritable Bowel Syndrome · University of California, Los Angeles.

Enrollment
5th of 11
65 · median 58
Started
2021
the only one that year
No phase
11 of 15
2 open now
Registered
13th of 15
by date

Among the 15 studies in Irritable Bowel Syndrome by University of California, Los Angeles, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2021, is one of 11 with no phase, and was the 13th registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

2 of the 15 studies in Irritable Bowel Syndrome by University of California, Los Angeles are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Irritable Bowel Syndrome by University of California, Los Angeles, or all of them as a file.
02

Study summary

Cognitive Behavioral Therapy (CBT) is the most well researched and most effective treatment for IBS targeting the brain-gut-microbiome (BGM) axis, and preliminary data show that this therapeutic effect is associated with a reduction of brainstem connectivity with other brain networks.

The increased prevalence of IBS in women, the higher rate of comorbid non-GI pain conditions, as well as the higher prevalence in female IBS of increased sensitivity to a variety of internal and external stimuli (multisensory sensitivity) suggest the presence of important sex differences in some of these BGM mechanisms.

Research performed by UCLA SCOR during previous funding has established an increased responsiveness of the CRF-Locus Coeruleus (LCC) system in female IBS subjects, suggesting that this central noradrenergic brainstem system plays an important role in IBS pathophysiology.

In addition, the study team's earlier research has begun to identify clinical, functional and structural brain mechanisms that may underlie these sex effects. Based on the preliminary data, the overall goal of this project is to use CBT as a probe to study the relationship between specific disease-related alterations of the brain, the gut microbiome, and symptomatic outcome, and identify the role of sex differences in these relationships. Investigators will study male and female IBS patients before and after CBT using the advanced neuroimaging and microbiome technologies of the overall SCOR.

Read the detailed description

A total of 150 adult IBS participants will be completed in years 1-4 of the proposed studies. These will be 50 males, 50 premenopausal females in the treatment arm (Cognitive behavioral therapy: CBT) and 50 in 'usual care' arm, all bowel habit subtypes.

Screening V1: All subjects will have a pre-screening using a study specific IRB approved prescreening tool (15-20 minutes). lf eligible and interested, the study team will send the ICF via email to the subject and then study team will review the ICF with the subject to determine understanding of study participation and risks/benefits. Subjects will sign and return to the coordinator by electronic/scan/fax methods. The study team will then send participants a short link of preliminary questionnaires via survey Monkey to further determine eligibility for participation and assist the clinician in obtaining accurate medical history as well as assess any risk factors of participation. When determined to be eligible, the study team will set up a video/zoom /phone meeting to complete the initial screening visit/medical and psychological history taking. This will take about 1.5 hour.

Subjects will come to the OCNSR center to complete the study screening, including a physical exam by the RN and RN/NP or MD. Upon arrival, they will date and sign the informed consent and have time to ask any questions. The physical exam will include vital signs, height, weight, and a ROS (review of systems). There will be a single blood sample taken of about 2 teaspoons to determine menstrual cycle (females) and if needed, there may be additional blood (about 1 tablespoon) for IBS-diarrhea or mixed predominance to rule out any other gastrointestinal disease similar to IBS symptoms. Subjects will be given sample collection items to take home for stool and diet diary collection. The stool sample will be collected when they return for the scheduled MRI within 1-3 weeks of screening. They will be given two unique de-identified online Survey Monkey links to complete before the MRI visit. One link is a Diet History Questionnaires (VioScreen) and the other is a group of questionnaires asking about symptoms (IBS), mood and general health and wellbeing. This visit will take about 1.5-2 hours.

MRI V2: Brain and Brainstem Data Acquisition: All participants will undergo a 70 minute structural, resting state, DTI and brain stem MRI scanning session. All subjects will be imaged on a Siemens 3 Tesla Prisma scanner housed at the UCLA Ahmanson-Lovelace Brain Mapping Center (ALBMC). Subjects will complete several state anxiety and symptom-measuring questionnaires upon arrival . Females will need to do daily urine test at home to identify their menstrual phase. When arriving to MRI they will give a urine sample for pregnancy testing and will be excluded if pregnant. A single blood sample will be collected via venipuncture for hormones, cell methylation and pro inflammatory cytokines (15-20 ccs). Subjects will return with their diet diary, stool and saliva (female) sample collections and have all samples reviewed by study coordinator, for viability and collection accuracy.

Scanning will follow parameters of the HBC (Human Brain Connectome) project with anterior and posterior views for each scan. They will have the structural MP Rage (gray matter imaging) scan (time \~14.5 minutes) and subjects can watch a movie of their choice during this scan.

Following this is 2 RSN (resting state) functional scan (total time \~12 minutes). Instructions verbatim are given to subject during the RSN to rest, relax and focus on the crosshair displayed on mirrored screen reflected on the head coil without going to sleep. Following the resting state scan the subject will be asked if they had any pain or discomfort anywhere that may have distracted the subject during the functional resting state and this will be documented on a subject chart.

The next scan is the DTI (diffusion tensor imaging) lasting approximately 10 minutes. Subjects can watch a movie of their choice during this scan.

This visit will take no more than 1.5-2 hours.

Subjects will then be randomized to CBT (66.5 % chance) or usual care (33.5 % chance). The CBT is described below. If usual care, the subject will not have any restrictions on subjects except that the study team will ask subjects not to start new therapies for IBS or new medicines unless it is deemed necessary by their PCP.

CBT: This structured educational and skills based intervention is carried out via internet instruction and individual practice. Subjects will be asked to log into the CBT site once per week for 8-10 weeks with each session lasting between 20 and 40 minutes. The content has been validated in a randomized internet-based CBT trial for IBS. The intervention does not entail any direct therapist contact or interaction with other patients or study participants. The intervention is hosted by Mahana Therapeutics Inc. (named Parallel TM) who is contracted by UCLA to provide the intervention. Following enrollment, each subject will receive a secure login for accessing the CBT site and no personally identifying information will be asked for or passed along to the site or Mahana Therapeutics. During the 8 week intervention period subjects will be contacted by a study coordinator for follow-up should they stop logging in to the web site and they will be able to contact a study coordinator with questions regarding the intervention, website access, etc.

A responder will be defined as a subject with IBS-SSS score change of ≥50 from baseline to end of treatment and corresponds to a clinically meaningful change in symptoms. Participants assigned to the Usual Care condition will have the same questionnaire, neuroimaging, biological and symptom assessments as those in CBT but will not have any specific intervention from the project.

There will be a short mid study SM questionnaire link to complete related to symptoms. After 8-10 weeks of CBT (within 2-3 weeks of completion) they will return for a post-CBT MRI visit identical to description above.

03

Conditions studied

  • IBS - Irritable Bowel Syndrome

Keywords

  • CBT
  • MRI
  • IBS
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 55 years of age, inclusive.
  2. Diagnosis or symptoms of Irritable Bowel Syndrome (IBS) meeting ROME IV diagnostic criteria for IBS (all sub-types).
  3. Must be absent of red flags including unexplained weight loss, fevers, anemia or blood in stools.
  4. Females must be premenopausal menstruating females. If female and of must be not pregnant, post-partum or breast feeding for at least 6 months. Must have a negative urine test for pregnancy. Must be willing to avoid pregnancy and practice a non-hormonal method such as abstinence, non-hormonal IUD's, or barrier method with spermicide, during the time of study enrollment. Subjects who are on hormonal based birth control (e.g OCP's or implants) will be allowed in the study as long as they still get a monthly menses so menstrual phase can be identified using ovulation kits.
  5. Ambulatory outpatient (not depending exclusively on a wheelchair for mobility)
  6. Ability to speak the English language fluently due to the standardized assessments involved.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of structural abnormality of the gastrointestinal tract. Exclusionary GI conditions include but are not limited to gastrointestinal surgery (exceptions: appendectomy, benign polypectomy, cholecystectomy).
  2. Presence of a significant and ongoing medical problem that would interfere with participation in the study or testing the study hypotheses (e.g., major heart disease, neurological disorders, inflammatory diseases such as IBD; esophagitis, celiac disease, gastrointestinal or obstruction, peptic, duodenal or gastric ulcer disease, etc.). Malignancy (other than localized skin cancer that has been resected) within the previous 5 years.
  3. Presence of a major psychiatric diagnosis such as schizophrenia, Bipolar disorder, current ADD diagnosis, Post-traumatic Stress Disorder, Obsessive Compulsive disorder or current history of tobacco or alcohol abuse. Subjects with a history of DSMIV diagnosis of Anxiety or Depression in whom symptoms are not active, will be allowed but noted for post-hoc analysis.
  4. Use of drugs, products or devices within 28 days prior to screen and through study participation.
  5. Subjects with current regular use of narcotics and or opioids. Use of centrally acting medications that will interfere with the neuroimaging testing (such as systemic , opiate analgesics). Medications which alter GI motility and gastric pH will need to be stopped at least 72 hours prior to any physiologic test visit and during the baseline and treatment intervention. For this we will ask the subject to get approval from their own PCP to stop prior to any intervention. However, rescue medication of bisacodyl and loperamide will be allowed for prolonged constipation and diarrhea, respectively, during intervention periods but not during baseline or within 3 days of follow up MRI. For rescue medication, such as laxatives or antidiarrheal, we will ask to hold off use up to 3 days prior to collecting stool sample.
  6. Obesity ( >35)
  7. Subjects with claustrophobia, metal implants, dental braces, large tattoos (e.g. full arm or back); making MRI safety not possible.
  8. History of heavy use of tobacco products or current use of more than 1/3 ppd.
  9. Plans to undergo a major medical intervention such a surgery within 6 months of enrollment or during the study, or had major surgery in last 6 months.
  10. Current or past history of chronic pain syndrome other than IBS in the IBS group (pain >6 months at any location).
  11. Use of antibiotics or probiotics within 3 months of the study enrollment or regular use of probiotics within 4 weeks of enrollment. (enrollment may be deferred)
  12. Subjects who currently actively practice CBT or have completed a CBT therapy within 2 years prior to enrolling.
  13. Must must have a score of ≥175 (at least moderate severity IBS) on the IB-SSS symptom severity scale completed at screening.
  14. Have an average abdominal pain of at least 3 on a 0-10 point scale where 0=no pain and 10=worst imaginable pain.
  15. Any other condition that the investigator believes would jeopardize the safety or rights of the subject or would render the subject unable to comply with the study protocol or make use of acquired data non-analyzable.

    -

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Cognitive Behavioral Treatment Arm

    Subjects in the "Cognitive Behavioral Treatment" Arm will undergo 8-10 weeks of remote cognitive behavioral therapy. Subjects will complete modules on their phones and will be monitored by study coordinators for support and treatment completion.

    Behavioral: COGNITIVE BEHAVIORAL THERAPY

  • No intervention
    Usual Care Arm

    Subjects in the "Usual Care" Arm will undergo 8-10 weeks of continued lifestyle. Subjects will be asked to report any new medications or lifestyle changes to study coordinators throughout the 8-10 weeks.

Interventions

  • BehavioralCOGNITIVE BEHAVIORAL THERAPY

    8-10 week self directed on line CBT program approved by FDA

06

What researchers measure

Primary outcomes

  1. Degree of Connectivity Between Brainstem Nuclei and the Salience, Emotional Arousal and Sensorimotor Networks Brain Networks.

    ROI (Region of Interest)-to-ROI connection pairs from resting-state fMRI data were computed and extracted to test functional connectivity between brainstem nuclei (Bstem) and the salience (SN), emotional arousal (EAN), and sensorimotor (SMN) networks. Participant-level composite scores were calculated by averaging connectivity values (Z transformed R values) across all ROI pairs within each unique network target for a total of 10 intrinsic and extrinsic network connections. Pre to post treatment mean changes in these composite scores were tested for differences between the usual care and CBT treatment groups using apriori contrast analyses with in the frame work of a linear mixed effects model , i.e. (CBT BL - CBT Post) - (UsualCare BL - UsualCare Post). Results are reported as the estimate marginal mean difference (estimate) and standard error (SE), the t statistic, the probability (p) and the 5% False Discovery Rate corrected p value (q) , and Cohen's effect size D with 95% CIs.

    Time frame: Before and after completion of 10 weeks of intervention or usual care.

  2. Irritable Bowel Symptom Severity Scale (IBSSS)

    The IBSSS is a validated composite symptom measure for severity of IBS symptoms. It will be used to determine treatment responder (\>50 point change pre to post treatment). Outcome measures the number of patients imporved in each groups (e.g. number of patients who had a \>50pts change on IBS-SSS).

    Time frame: Before and after completion of 10 weeks of intervention or usual care.

Secondary outcomes

  1. Abundance of Clostridiales Taxa

    Stool sample taken pre and post treatment will be processed according to standard laboratory procedures and levels of Clostridiales determined.

    Time frame: Through study completion, an average of 2 years 11 months

  2. Level of Tryptophan Metabolites

    Plasma sample taken pre and post treatment will be processed according to standard laboratory procedures and levels of tryptophan metabolites determined.

    Time frame: Through study completion, an average of 2 years 11 months

  3. KYN/TR Ratio.

    Plasma samples taken pre and post treatment will be processed according to standard laboratory procedures and KYN/TR ration determined.

    Time frame: Through study completion, an average of 2 years 11 months

07

Results

Posted Nov 5, 2026
Limitations and caveats
Early termination due to unexpected closure of Mahana app. This caused a premature end to study enrollment.

Participant flow

Participant flow — Overall Study
MilestoneCognitive Behavioral Treatment ArmUsual Care Arm
Started4520
Completed3718
Not completed82

Outcome measures

PrimaryDegree of Connectivity Between Brainstem Nuclei and the Salience, Emotional Arousal and Sensorimotor Networks Brain Networks.

ROI (Region of Interest)-to-ROI connection pairs from resting-state fMRI data were computed and extracted to test functional connectivity between brainstem nuclei (Bstem) and the salience (SN), emotional arousal (EAN), and sensorimotor (SMN) networks. Participant-level composite scores were calculated by averaging connectivity values (Z transformed R values) across all ROI pairs within each unique network target for a total of 10 intrinsic and extrinsic network connections. Pre to post treatment mean changes in these composite scores were tested for differences between the usual care and CBT treatment groups using apriori contrast analyses with in the frame work of a linear mixed effects model , i.e. (CBT BL - CBT Post) - (UsualCare BL - UsualCare Post). Results are reported as the estimate marginal mean difference (estimate) and standard error (SE), the t statistic, the probability (p) and the 5% False Discovery Rate corrected p value (q) , and Cohen's effect size D with 95% CIs.

Time frame:
Before and after completion of 10 weeks of intervention or usual care.
Reported as:
Mean · Z transformed R values
Degree of Connectivity Between Brainstem Nuclei and the Salience, Emotional Arousal and Sensorimotor Networks Brain Networks.
Z transformed R valuesCognitive Behavioral Treatment ArmUsual Care Arm
Bstem_to_EAN-0.02 ± 0.010.03 ± 0.01
EAN_to_SN-0.02 ± 0.010.05 ± 0.02
Bstem_to_Bstem-0.01 ± 0.010.06 ± 0.02
EAN_to_EAN-0.01 ± 0.010.01 ± 0.02
EAN_to_SMN-0.01 ± 0.01-0.02 ± 0.02
SMN_to_SMN0.01 ± 0.010.01 ± 0.02
SMN_to_SN0.01 ± 0.010.01 ± 0.01
Bstem_to_SN-0.01 ± 0.010.01 ± 0.01
SN_to_SN0.01 ± 0.020.01 ± 0.03
Bstem_to_SMN0.00 ± 0.010.01 ± 0.02
PrimaryIrritable Bowel Symptom Severity Scale (IBSSS)

The IBSSS is a validated composite symptom measure for severity of IBS symptoms. It will be used to determine treatment responder (\>50 point change pre to post treatment). Outcome measures the number of patients imporved in each groups (e.g. number of patients who had a \>50pts change on IBS-SSS).

Time frame:
Before and after completion of 10 weeks of intervention or usual care.
Reported as:
Count of participants · Participants
Irritable Bowel Symptom Severity Scale (IBSSS)
ParticipantsCognitive Behavioral Treatment ArmUsual Care Arm
Irritable Bowel Symptom Severity Scale (IBSSS)194
SecondaryAbundance of Clostridiales Taxa

Stool sample taken pre and post treatment will be processed according to standard laboratory procedures and levels of Clostridiales determined.

Time frame:
Through study completion, an average of 2 years 11 months

Results for this outcome have not been posted.

SecondaryLevel of Tryptophan Metabolites

Plasma sample taken pre and post treatment will be processed according to standard laboratory procedures and levels of tryptophan metabolites determined.

Time frame:
Through study completion, an average of 2 years 11 months

Results for this outcome have not been posted.

SecondaryKYN/TR Ratio.

Plasma samples taken pre and post treatment will be processed according to standard laboratory procedures and KYN/TR ration determined.

Time frame:
Through study completion, an average of 2 years 11 months

Results for this outcome have not been posted.

Adverse events

Collected over Through study completion, an average of 6 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cognitive Behavioral Treatment Arm0/45 (0%)0/45 (0%)0/45 (0%)
Usual Care Arm0/20 (0%)0/20 (0%)0/20 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cognitive Behavioral Treatment ArmUsual Care ArmTotal
<=18 years000
Between 18 and 65 years371855
>=65 years000
Age, Continuous
Age, Continuous(years)Cognitive Behavioral Treatment ArmUsual Care ArmTotal
Mean28.19 ± 6.0228.39 ± 8.4128.25 ± 6.89
Sex: Female, Male
Sex: Female, Male(Participants)Cognitive Behavioral Treatment ArmUsual Care ArmTotal
Female281442
Male9413
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cognitive Behavioral Treatment ArmUsual Care ArmTotal
Hispanic or Latino459
Not Hispanic or Latino331346
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cognitive Behavioral Treatment ArmUsual Care ArmTotal
American Indian or Alaska Native000
Asian9514
Native Hawaiian or Other Pacific Islander000
Black or African American314
White19928
More than one race235
Unknown or Not Reported404
Region of Enrollment
Region of Enrollment(participants)Cognitive Behavioral Treatment ArmUsual Care ArmTotal
United States452065
08

Study locations

1 site
  • UCLA
    Los Angeles, California 90095, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2021 to primary completion in Nov 2024, 34 months.

Results were first posted in Nov 2026, 1 year 11 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2024 → Nov 2024 and completion Jan 2025 → Nov 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Dec 13, 2021
StartActual
Dec 18, 2021
Primary completionActual
Nov 8, 2024was Dec 2024
CompletionActual
Nov 19, 2024was Jan 2025
Results first posted
Nov 5, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated Early termination due to unexpected closure of Mahana app. This caused a premature end to study enrollment.
changed Nov 5, 2026
Results
Results posted
posted Nov 5, 2026
Primary completion
Dec 12, 2024→Nov 8, 2024
Nov 5, 2026
Study completion
Jan 1, 2025→Nov 19, 2024
Nov 5, 2026
Enrollment
92→65
Nov 5, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedDegree of connectivity between brainstem nucleiConnectivity Between Brainstem Nuclei and the salienceSalience, emotional arousalEmotional Arousal and sensorimotor networks brain networksSensorimotor Networks Brain Networks.Time frame: Through study completion, an average of 5 years → Before and after completion of 10 weeks of intervention or usual care.
  • AddedIrritable Bowel Symptom Severity Scale (IBSSS)Time frame: Before and after completion of 10 weeks of intervention or usual care.
Nov 5, 2026
Secondary outcomes
3 edited, 1 removed
What changed in the outcomes
  • EditedAbundance of Clostridiales taxaTaxaTime frame: Through study completion, an average of 5 years → Through study completion, an average of 2 years 11 months
  • EditedLevel of tryptophan metabolitesTryptophan MetabolitesTime frame: Through study completion, an average of 5 years → Through study completion, an average of 2 years 11 months
  • EditedKYN/TR ratioRatio.Time frame: Through study completion, an average of 5 years → Through study completion, an average of 2 years 11 months
  • RemovedIrritable Bowel Symptom Severity scale (IBSSS)Time frame: Through study completion, an average of 5 years
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Completed→Terminated
    Why stopped Early termination due to unexpected closure of Mahana app. This caused a premature end to study enrollment.
    Results posted
    Primary completion Dec 12, 2024→Nov 8, 2024
    Study completion Jan 1, 2025→Nov 19, 2024
    Enrollment 92→65
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedDegree of connectivity between brainstem nucleiConnectivity Between Brainstem Nuclei and the salienceSalience, emotional arousalEmotional Arousal and sensorimotor networks brain networksSensorimotor Networks Brain Networks.Time frame: Through study completion, an average of 5 years → Before and after completion of 10 weeks of intervention or usual care.
    • AddedIrritable Bowel Symptom Severity Scale (IBSSS)Time frame: Before and after completion of 10 weeks of intervention or usual care.
    Secondary outcomes 3 edited, 1 removed
    What changed in the outcomes
    • EditedAbundance of Clostridiales taxaTaxaTime frame: Through study completion, an average of 5 years → Through study completion, an average of 2 years 11 months
    • EditedLevel of tryptophan metabolitesTryptophan MetabolitesTime frame: Through study completion, an average of 5 years → Through study completion, an average of 2 years 11 months
    • EditedKYN/TR ratioRatio.Time frame: Through study completion, an average of 5 years → Through study completion, an average of 2 years 11 months
    • RemovedIrritable Bowel Symptom Severity scale (IBSSS)Time frame: Through study completion, an average of 5 years
    + 3 other changes: verification date, criteria formatting and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05155631
Responsible party
Emeran Mayer, MD (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Dec 13, 2021
Start date
Dec 18, 2021
Primary completion
Nov 8, 2024
Completion
Nov 19, 2024
Results posted
Nov 5, 2026
Last update
Nov 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion